{
    "nctId": "NCT05285332",
    "briefTitle": "Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy",
    "officialTitle": "Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapywhich Patients Will Benefit From Surgery",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Neoplasms, Treatment, Metastatic Breast Cancer, Survival",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 362,
    "primaryOutcomeMeasure": "Overall survival",
    "eligibilityCriteria": "Study Population Operable stage IV breast cancer patients, whose primary lesion is invasive breast cancer confirmed by pathology, and metastases can be confirmed by pathology or imaginology examination\n\nInclusion Criteria:\n\n* Operable stage IV breast cancer patients,whose primary lesion is invasive breast cancer confirmed by pathology, and metastases can be confirmed by pathology or imageology examination.\n* ECOG-PS 0-2.\n* Bone marrow, liver and kidney should be fully functional.\n* Patients didn't received the locoregional surgery of the primary tumor in de novo.\n* For the patient who accepted systematic treatment before operation, the systematic treatment must be administered within a year since diagnosed.\n\nExclusion Criteria:\n\n* Accompanied with other primary malignant tumors.\n* More than two visceral organ involvement.\n* Patients who can't plan for follow-up effectively and regularly.\n* Multiple liver metastases with deranged liver function tests (SGOT/SGPT more than four times the upper normal limit).",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}